Pharmacy Website
    Clinic Website

    Intelligence » Leukemia » Last Week

    Subscribe to get latest posts via email or subscribe to a RSS feed.

    First new hairy cell leukemia drug in 20 years approved, but will it make a dent?

    Monday, September 17, 2018 -- While AstraZeneca touted Lumoxiti as the first new therapy for HCL in 20 years, a leukemia expert downplayed the significance of the trial data that led to the approval.

    Targeted therapy for fusion-driven high-risk acute leukemia

    Thursday, September 20, 2018 -- Despite continued progress in drug development for acute leukemias, outcomes for patients with some subtypes have not changed significantly in the last decade. Recurrent chromosomal translocations have long been recognized as driver events in leukemia, and many of these oncogenic fusions portend high-risk disease. Improved understanding of the molecular underpinnings of these fusions, coupled with novel chemistry approaches, now provide new opportunity for therapeutic inroads into the treatment of leukemia driven by these fusions.

    Higher-Dose Immunoglobulin Replacement Therapy in Chronic Lymphocytic Leukemia

    Thursday, September 20, 2018 -- Investigators found that dosing of IgRT in CLL at target levels higher than conventional parameters may offer a therapeutic benefit.

    FDA Approves New Kind of Treatment for Hairy Cell Leukemia

    Tuesday, September 18, 2018 -- NewsThe U.S. Food and Drug Administration approved Lumoxiti injection for intravenous use for the treatment of adult patients with hairy cell leukemia.Contributed Author: FDATopics: Orphan Drugs